Abstract | BACKGROUND: METHODS AND RESULTS:
Bepridil (50-200 mg/day) was given to 76 patients with either paroxysmal (n=49) or persistent AF (n=27). All patients had been treated with class I AADs (1.9+/-0.9 drugs/patient) that failed to control the AF. With the addition of bepridil, the frequency of symptomatic AF episodes decreased to less than 10% in 38 (78%) patients with paroxysmal AF, and sinus rhythm was restored within 3 months and maintained during the follow-up in 20 (74%) patients with persistent AF. Efficacy was usually obtained with a small to moderate dose (50-150 mg/day) of bepridil. During a mean follow-up period of 27+/-22 months, no potential complications occurred in any of the patients. CONCLUSIONS: The addition of bepridil to class I AADs is effective and safe for AF, but careful observation using periodic ECG recordings is essential for avoiding torsades de pointes caused by QT prolongation.
|
Authors | Kohei Miyaji, Hiroshi Tada, Kengo Fukushima Kusano, Tohru Hashimoto, Kenichi Kaseno, Shigeki Hiramatsu, Kazuyoshi Tadokoro, Shigeto Naito, Kazufumi Nakamura, Shigeru Oshima, Koichi Taniguchi, Tohru Ohe |
Journal | Circulation journal : official journal of the Japanese Circulation Society
(Circ J)
Vol. 71
Issue 8
Pg. 1250-7
(Aug 2007)
ISSN: 1346-9843 [Print] Japan |
PMID | 17652890
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Anti-Arrhythmia Agents
- Bepridil
|
Topics |
- Aged
- Anti-Arrhythmia Agents
(therapeutic use)
- Atrial Fibrillation
(drug therapy)
- Bepridil
(administration & dosage)
- Drug Therapy, Combination
- Electrocardiography
- Female
- Humans
- Long QT Syndrome
(prevention & control)
- Male
- Middle Aged
- Salvage Therapy
(methods)
- Torsades de Pointes
(prevention & control)
- Treatment Outcome
|